AZYO Aziyo Biologics

Elutia to Participate in Upcoming Investor Conferences

Elutia to Participate in Upcoming Investor Conferences

SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences:

LD Micro 15th Annual Invitational – New York, NY

Format: Presentation and 1x1 Meetings

Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)

Webcast:

Planet Microcap Showcase – Las Vegas, NV

Format: Presentation and 1x1 Meetings

Presentation Date and Time: Wednesday, April 23, 2025, 4:00 p.m. ET (1:00 p.m. PT)

Webcast:

Elutia management will also participate in 1x1 investor meetings. Institutional investors interested in scheduling a meeting may contact an LD Micro or Planet Microcap representative or email .

About Elutia

Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit .

Investors:

Matt Steinberg

FINN Partners

This press release was published by a CLEAR® Verified individual.



EN
03/04/2025

Underlying

AZYOAziyo Biologics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aziyo Biologics

 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Participate in Upcoming Investor Conferences

Elutia to Participate in Upcoming Investor Conferences SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences: LD Micro 15th Annual Invitational – New York, NYFormat: Presentation and 1x1 Meetings Presentation Date and Time: Thursday, April 10, 2025, 12:30 p.m. ET (9:30 a.m. PT)Webcast: Planet Microcap Showcase – Las...

19h / 41m 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biolog...

Elutia to Debut EluPro™ at HRS 2025 — Experience the Difference Biology Makes Introduction of EluPro at Heart Rhythm 2025 in San Diego, April 25-27, 2025 SILVER SPRING, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, is proud to announce the debut of its EluPro™ Antibiotic-Eluting BioEnvelope designed for cardiac implantable electronic devices (CIEDs) and neurostimulators at the Heart Rhythm Society’s annual meeting (HRS 2025). Attendees will have the opportunity to experience firsthand the soft...

April 2, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces GPO Agreement with Advantus Health Partners to Expand...

Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™ Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement with Advantus Health Partners (“Advantus”), to provide access of Elutia’s EluPro™ Antibiotic Eluting BioEnvelope to Advantus’ core group purchasing organizations (GPO) solutions portfolio. “Teaming up with Advantus is another major step forward in ...

March 27, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Advances Scientific Leadership with Publication of New Study on...

Elutia Advances Scientific Leadership with Publication of New Study on Antibiotic-Eluting Biologic Envelope — Rigorous testing demonstrates robust antimicrobial performance against bacterial strains relevant to cardiac implanted electronic device (CIED) infections — SILVER SPRING, Md., March 25, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the publication of new preclinical data in the current issue of , further demonstrating the antimicrobial performance of its antibiotic-eluting biolo...

March 25, 2025 1 EN
 PRESS RELEASE
Free
AZYO AZIYO BIOLOGICS

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: ...

Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out – Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the fourth quarter and full year ended December 31, 2024. Business Highlights: Strong Initial Market Upta...

March 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch